Invention Grant
US09587028B2 Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
有权
亲和成熟的抗CCR4人源化单克隆抗体及其使用方法
- Patent Title: Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
- Patent Title (中): 亲和成熟的抗CCR4人源化单克隆抗体及其使用方法
-
Application No.: US14820882Application Date: 2015-08-07
-
Publication No.: US09587028B2Publication Date: 2017-03-07
- Inventor: Wayne A. Marasco , Jianhua Sui , Quan Zhu , De-Kuan Chang , Thomas S. Kupper
- Applicant: DANA-FARBER CANCER INSTITUTE, INC. , BRIGHAM AND WOMEN'S HOSPITAL, INC.
- Applicant Address: US MA Boston US MA Boston
- Assignee: Dana-Farber Cancer Institute, Inc.,Brigham and Women's Hospital
- Current Assignee: Dana-Farber Cancer Institute, Inc.,Brigham and Women's Hospital
- Current Assignee Address: US MA Boston US MA Boston
- Agency: Cooley LLP
- Agent Ivor Elrifi; Cynthia Kozakiewicz
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; C07K16/40 ; A61K47/48 ; A61K39/00
Abstract:
The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
Public/Granted literature
- US20160185865A1 AFFINITY MATURED ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE Public/Granted day:2016-06-30
Information query
